Lineage Cell Therapeutics (LCTX) Prepaid Assets (2010 - 2026)

Lineage Cell Therapeutics has reported Prepaid Assets for 17 years, with the latest figure at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Prepaid Assets rose 5.95% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (up 5.95% YoY), and the FY2025 full-year result was $2.5 million, down 2.7% from the prior year.
• Prepaid Assets for Q1 2026 stood at $2.0 million, down from $2.5 million in the prior quarter.
• The five-year high for Prepaid Assets was $2.6 million in Q1 2023, with the low at $1.3 million in Q3 2024.
• Historically, Prepaid Assets has averaged $1.9 million across 5 years, with a median of $1.8 million in 2022.
• Annual changes were most pronounced in 2022 — Prepaid Assets tumbled 48.54% — and 2023, when it jumped 86.69%.
• Lineage Cell Therapeutics' Prepaid Assets stood at $1.8 million in 2022, then advanced by 20.57% to $2.2 million in 2023, then gained by 15.88% to $2.6 million in 2024, then retreated by 2.7% to $2.5 million in 2025, then slipped by 20.44% to $2.0 million in 2026.
• The last three Prepaid Assets figures came in at $2.0 million (Q1 2026), $2.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.